 |
Atovaquone |
|---|---|
| Trade Name | Mepron |
| Orphan Indication | Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3 |
| USA Market Approval | USA |
| USA Designation Date | 1991-08-14 00:00:00 |
| Sponsor | Glaxo Wellcome Research and Development;5 Moore Drive, PO Box 13398;Research Triangle Park, North Carolina, 27709 |
